We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Takeda Pharmaceutical Company Ltd | NYSE:TAK | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.34 | 2.59% | 13.45 | 13.49 | 13.40 | 13.40 | 1,458,429 | 22:09:56 |
By Stephen Nakrosis
Pharmaceutical company Takeda said Wednesday that the U.S. Food and Drug Administration approved Fruzaqla as a treatment for certain patients with colorectal cancer.
Fruzaqla, or fruquintinib, an oral targeted therapy, was approved for adults with metastatic colorectal cancer who had received certain previous treatments for the condition.
The company said Fruzaqla and best supportive care showed "significant improvements in overall survival, with corresponding improvements in progression free survival, versus placebo plus best supportive care in two Phase 3 clinical trials."
Data from the trials supported an EU marketing authorization application for fruquintinib, "which was validated and accepted for review by the European Medicines Agency in June," Takeda said. A submission was made in September to the Japan Pharmaceuticals and Medical Devices Agency, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 08, 2023 18:34 ET (23:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Takeda Pharmaceutical Chart |
1 Month Takeda Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions